FDA Grants Priority Vouchers to Three Psychedelic Drug Programs
The FDA announced Friday that it issued three Commissioner’s National Priority Vouchers to psychedelic drug programs. The agency selected Compass Pathways, Usona Institute, and Otsuka Pharmaceutical. The decision could deliver the first psychedelic medicine approved by the FDA as soon as this summer.
New:Â Get Pre-Screened for a Psychedelic Clinical Trial
| Key Takeaway | Details |
|---|---|
| Voucher recipients | Compass Pathways, Usona Institute, and Otsuka Pharmaceutical |
| Conditions targeted | Depression resistant to standard care, major depression, and PTSD |
| Timeline impact | Review shrinks from 10 to 12 months down to one or two months |
| First approval possible | Commissioner Makary says as soon as end of summer 2026 |
| Policy backdrop | Follows Trump’s April 18 executive order on psychedelic research |
| Notable snub | Resilient Pharmaceuticals received no voucher despite expectations |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
What the Vouchers Mean
Commissioner’s National Priority Vouchers compress FDA review timelines dramatically. A typical new drug application takes 10 to 12 months. With a voucher, that window shrinks to just one or two months. Eli Lilly’s weight loss pill Foundayo earned approval only 50 days after submission under the same program earlier this month.
FDA Commissioner Marty Makary told NBC News the first psychedelic drug could secure approval by the end of summer. The announcement follows President Trump’s executive order signed April 18. That order committed federal resources to accelerating psychedelic research and patient access.
Compass Pathways Leads the Pack
Compass Pathways secured a voucher for COMP360, its psilocybin therapy for depression that resists standard treatment. The company recently shared topline data from its second Phase 3 trial. It plans to submit its application in the fourth quarter.
The decision reverses an earlier setback. Last October, the White House vetoed a draft voucher list that included Compass, reportedly over political optics. The company first earned Breakthrough Therapy designation in late 2018.
Usona Institute Enters the Race
Usona Institute, a nonprofit drug developer, received a voucher for its psilocybin program targeting major depressive disorder. The organization earned Breakthrough Therapy designation in 2019. Usona plans to submit its application on the basis of a single Phase 3 study.
That timeline places Usona close to Compass, which could spark a competitive scramble. Usona lacks a visible commercial team and may need a partner to launch the drug. Patent disputes with Compass could further complicate any rollout.
Otsuka’s Surprise Selection
The third voucher went to Otsuka Pharmaceutical for methylone, known as TSND-201, targeting PTSD. Otsuka is acquiring the compound from Transcend Therapeutics in a $1.23 billion deal. The program is entering Phase 3, making it the least mature of the three.
The selection surprised industry analysts. Many expected the voucher to go to Resilient Pharmaceuticals, formerly Lykos Therapeutics. Resilient received a Complete Response Letter in 2024 for its MDMA therapy. The company has not launched a new Phase 3 study since.
What This Means for Patients
The vouchers arrive as millions of Americans continue to struggle with depression and PTSD. Rigorous science remains essential, and experts caution that speed must not compromise safety standards. Still, Friday’s announcement signals that new treatment options may reach patients far sooner than many predicted.
